Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A prospective, multicenter, observational evaluation of the safety and efficacy of the FRED® device in the treatment of intracranial aneurysms
This is a multi-center observational study. Treatment and follow-up visits will be performed as per standard of care. The purpose of this study is to demonstrate that use of the FRED/ FRED Jr/ FRED X Embolic device in intracranial aneurysm treatment is safe and effective when assessed at 6, 12 months and yearly up to 5 years post procedure.
150 patients will be enrolled over an 15-month recruitment period. All patients will be followed for 5 years.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| FRED, FRED Jr and FRED X | Device | Subjects aged ≥ 18 requiring treatment for an unruptured or recanalized intracranial aneurysm |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of complete aneurysm occlusion without associated stenosis of the parent artery (> 50%) | Complete occlusion (Raymond Scale grade I) without stenosis of the parent artery. Raymond scale definition: Grade I= complete occlusion of aneurysm, Grade II= Residual neck, Grade III= Residual aneurysm | 12 months |
| Morbidity Rate | Patients with mRS>2 | 6 months |
| Mortality Rate | Deaths within 6 months after treatment | 6 months |
Not provided
Not provided
Inclusion Criteria:
Patient older than 18 years old
Patient harboring a non-acutely ruptured intracranial aneurysm within the last 30 days of presentation:
Patient with a modified Rankin Scale (mRS) ≤ 2
Patient has received information about data collection and has signed and dated an Informed Consent Form
Exclusion Criteria:
Patient has suffered from an ICH within the 30 days prior to the procedure.
The aneurysm to be treated is associated with a cAVM
The aneurysm to be treated is in the posterior circulation
The aneurysm to be treated has a stenosis of its parent artery >50%
Patient has another aneurysm previously treated with a stent or a flow diverter
Patient with whom anticoagulant, antiplatelet or thrombolytic drugs are contra-indicated or test performed regarding AP medication administered is not efficient for the patient
Patient with known hypersensitivity to contrast products or nickel titanium, not treatable
Pregnancy or child breastfeeding
Patient unable or unlikely to complete required follow up
Patient has severe or fatal comorbidity or a life expectancy of less than 1 year
Treatment with a flow diverter other than FRED/ FRED Jr/ FRED X or in addition to FRED/ FRED Jr/ FRED X is planned
Not provided
Not provided
Not provided
Patients who are at least 18 years of age presenting with an unruptured or recanalized intracranial aneurysm requiring endovascular treatment. Those eligible to be treated with FRED/ FRED Jr/ FRED X will be enrolled after having signed an informed consent form.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Arnd Dörfler, Prof. Dr. med. | Universitätsklinikum Erlangen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitätsklinikum Erlangen | Erlangen | D-91054 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002532 | Intracranial Aneurysm |
| ID | Term |
|---|---|
| D020765 | Intracranial Arterial Diseases |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009422 | Nervous System Diseases |
| D000783 | Aneurysm |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |